Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study

Background 70%–84% of individuals with antipsychotic treatment resistance show non-response from the first episode. Emerging cross-sectional evidence comparing cognitive profiles in treatment resistant schizophrenia to treatment-responsive schizophrenia has indicated that verbal memory and language functions may be more impaired in treatment resistance. We sought to confirm this finding by comparing cognitive performance between antipsychotic non-responders (NR) and responders (R) using a brief cognitive battery for schizophrenia, with a primary focus on verbal tasks compared against other measures of cognition. Design Cross-sectional. Setting This cross-sectional study recruited antipsychotic treatment R and antipsychotic NR across four UK sites. Cognitive performance was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS). Participants One hundred and six participants aged 18–65 years with a diagnosis of schizophrenia or schizophreniform disorder were recruited according to their treatment response, with 52 NR and 54 R cases. Outcomes Composite and subscale scores of cognitive performance on the BACS. Group (R vs NR) differences in cognitive scores were investigated using univariable and multivariable linear regressions adjusted for age, gender and illness duration. Results Univariable regression models observed no significant differences between R and NR groups on any measure of the BACS, including verbal memory (ß=−1.99, 95% CI −6.63 to 2.66, p=0.398) and verbal fluency (ß=1.23, 95% CI −2.46 to 4.91, p=0.510). This pattern of findings was consistent in multivariable models. Conclusions The lack of group difference in cognition in our sample is likely due to a lack of clinical distinction between our groups. Future investigations should aim to use machine learning methods using longitudinal first episode samples to identify responder subtypes within schizophrenia, and how cognitive factors may interact within this. Trail registration number REC: 15/LO/0038.

[1]  A. Egerton,et al.  Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis , 2021, Psychological Medicine.

[2]  W. Honer,et al.  Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders. , 2020, Schizophrenia bulletin.

[3]  R. Emsley,et al.  Dopamine and Glutamate in Antipsychotic-Responsive Compared With Antipsychotic-Nonresponsive Psychosis: A Multicenter Positron Emission Tomography and Magnetic Resonance Spectroscopy Study (STRATA) , 2020, Schizophrenia bulletin.

[4]  E. Rostrup,et al.  Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis , 2020, Biological Psychiatry.

[5]  S. Dienel,et al.  Prefrontal cortical alterations of glutamate and GABA neurotransmission in schizophrenia: Insights for rational biomarker development , 2020, Biomarkers in neuropsychiatry.

[6]  A. Tanskanen,et al.  The clinical course of schizophrenia in women and men—a nation-wide cohort study , 2020, npj Schizophrenia.

[7]  E. Rostrup,et al.  Differential effects of age at illness onset on verbal memory functions in antipsychotic-naïve schizophrenia patients aged 12–43 years , 2020, Psychological Medicine.

[8]  C. Li,et al.  Hippocampus and cognitive domain deficits in treatment-resistant schizophrenia: A comparison with matched treatment-responsive patients and healthy controls✰,✰✰,★,★★ , 2020, Psychiatry Research: Neuroimaging.

[9]  K. Ryzhikova,et al.  Cognitive impairment in patients with treatment resistant schizophrenia: Associations with DRD2, DRD3, HTR2A, BDNF and CYP2D6 genetic polymorphisms , 2019, Neurology, Psychiatry and Brain Research.

[10]  R. Murray,et al.  Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies , 2019, Psychological Medicine.

[11]  Peter B. Jones,et al.  Cognitive Change in Schizophrenia and Other Psychoses in the Decade Following the First Episode. , 2019, The American journal of psychiatry.

[12]  G. Kirov,et al.  Clinical indicators of treatment-resistant psychosis , 2019, The British Journal of Psychiatry.

[13]  S. Potkin,et al.  Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. , 2019, The Journal of clinical psychiatry.

[14]  P. Bozzatello,et al.  Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review , 2019, Front. Psychiatry.

[15]  R. Burns,et al.  A Systematic Review of the Symptom Profile and Course of Methamphetamine-Associated Psychosis , 2019, Substance use & misuse.

[16]  Egill Rostrup,et al.  Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients , 2018, Psychological Medicine.

[17]  M. Fornaro,et al.  Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses , 2018, Psychiatry Research.

[18]  Peter B. Jones,et al.  Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ÆSOP-10 study , 2018, Psychological Medicine.

[19]  E. Bora,et al.  Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia , 2017, Psychological Medicine.

[20]  M. Medina-Mora,et al.  Validity of the posttraumatic stress disorders (PTSD) checklist in pregnant women , 2017, BMC Psychiatry.

[21]  R. Murray,et al.  Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors , 2017, Psychological Medicine.

[22]  C. Gasse,et al.  Predictors of Nonhospitalization and Functional Response in Clozapine Treatment: A Nationwide, Population-Based Cohort Study , 2017, Journal of clinical psychopharmacology.

[23]  L. K. Hansen,et al.  Two subgroups of antipsychotic-naive, first-episode schizophrenia patients identified with a Gaussian mixture model on cognition and electrophysiology , 2017, Translational Psychiatry.

[24]  Ryuhei So,et al.  The critical treatment window of clozapine in treatment-resistant schizophrenia: Secondary analysis of an observational study , 2017, Psychiatry Research.

[25]  A. Egerton,et al.  Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review , 2017, BMC Psychiatry.

[26]  F. Gaughran,et al.  Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics , 2016, Pharmacogenomics and personalized medicine.

[27]  R. Murray,et al.  Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses , 2016, Psychological Medicine.

[28]  C. Correll,et al.  Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study , 2016, CNS Drugs.

[29]  C. Gasse,et al.  Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. , 2016, The lancet. Psychiatry.

[30]  B. Misiak,et al.  Profiling cognitive impairment in treatment-resistant schizophrenia patients , 2016, Psychiatry Research.

[31]  J. MacCabe,et al.  Service users’ and carers’ views on research towards stratified medicine in psychiatry: a qualitative study , 2015, BMC Research Notes.

[32]  V. Mohan Faeco-prevalence of Campylobacter jejuni in urban wild birds and pets in New Zealand , 2015, BMC Research Notes.

[33]  L. Farde,et al.  Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia , 2014, Schizophrenia Research.

[34]  Philip D. Harvey What is the evidence for changes in cognition and functioning over the lifespan in patients with schizophrenia? , 2014, The Journal of clinical psychiatry.

[35]  F. Iasevoli,et al.  Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses , 2013, Psychiatry Research.

[36]  E. Stip,et al.  Clozapine and visuospatial processing in treatment-resistant schizophrenia , 2013, Cognitive neuropsychiatry.

[37]  J. O. Johannessen,et al.  Ten year neurocognitive trajectories in first-episode psychosis , 2013, Front. Hum. Neurosci..

[38]  T. Kosten,et al.  Gender differences in cognitive function of patients with chronic schizophrenia , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  A. Lobo,et al.  Negative Symptoms and Executive Function in Schizophrenia: Does Their Relationship Change with Illness Duration? , 2012, Psychopathology.

[40]  Jayashri Kulkarni,et al.  Gender Differences in Schizophrenia and First-Episode Psychosis: A Comprehensive Literature Review , 2012, Schizophrenia research and treatment.

[41]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[42]  Aysenil Belger,et al.  Attention deficits in schizophrenia — Preliminary evidence of dissociable transient and sustained deficits , 2010, Schizophrenia Research.

[43]  J. Peña,et al.  Verbal Fluency in Schizophrenia: Does Cognitive Performance Reflect the Same Underlying Mechanisms in Patients and Healthy Controls? , 2010, The Journal of nervous and mental disease.

[44]  Peter B. Jones,et al.  Neuropsychological functioning in first-episode schizophrenia , 2009, British Journal of Psychiatry.

[45]  S. Faraone,et al.  Neurocognition in first-episode schizophrenia: a meta-analytic review. , 2009, Neuropsychology.

[46]  A M McIntosh,et al.  Working memory in schizophrenia: a meta-analysis , 2008, Psychological Medicine.

[47]  Philip D. Harvey,et al.  Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS) , 2008, Schizophrenia Research.

[48]  A. Minassian,et al.  Stability of attention deficits in schizophrenia , 2007, Schizophrenia Research.

[49]  F. Craik,et al.  Cognition through the lifespan: mechanisms of change , 2006, Trends in Cognitive Sciences.

[50]  E. Kandel,et al.  Transient and Selective Overexpression of Dopamine D2 Receptors in the Striatum Causes Persistent Abnormalities in Prefrontal Cortex Functioning , 2006, Neuron.

[51]  Junghee Lee,et al.  Working memory impairments in schizophrenia: a meta-analysis. , 2005, Journal of abnormal psychology.

[52]  Cameron S Carter,et al.  Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. , 2005, Schizophrenia bulletin.

[53]  Philip McGuire,et al.  Association of symptoms and executive function in schizophrenia and bipolar disorder , 2005, Schizophrenia Research.

[54]  J. Sweeney,et al.  Impairment of verbal memory and learning in antipsychotic-naı̈ve patients with first-episode schizophrenia , 2004, Schizophrenia Research.

[55]  B. Wexler,et al.  Verbal memory in schizophrenia: additional evidence of subtypes having different cognitive deficits , 2004, Schizophrenia Research.

[56]  Philip D. Harvey,et al.  The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery , 2004, Schizophrenia Research.

[57]  R. Murray,et al.  Verbal memory deficit in patients with schizophrenia: an important future target for treatment , 2004, Expert review of neurotherapeutics.

[58]  T. Goldberg,et al.  Letter and category fluency in schizophrenic patients: a meta-analysis , 2003, Schizophrenia Research.

[59]  C. Benkelfat,et al.  Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers , 2002, Schizophrenia Research.

[60]  A. Arnsten Catecholamine modulation of prefrontal cortical cognitive function , 1998, Trends in Cognitive Sciences.

[61]  V. Peralta,et al.  Illness duration and neuropsychological impairments in schizophrenia. , 1998, Schizophrenia research.

[62]  G. Kirov,et al.  Randomised controlled trial of compliance therapy , 1998, British Journal of Psychiatry.

[63]  N. Andreasen,et al.  Soft signs and neuropsychological performance in schizophrenia. , 1996, The American journal of psychiatry.

[64]  P. Hayward,et al.  Compliance therapy in psychotic patients: randomised controlled trial , 1996, BMJ.

[65]  Klaus P. Ebmeier,et al.  Magnetic Resonance Imaging and Single Photon Emission Tomography in Treatment-Responsive and Treatment-Resistant Schizophrenia , 1995, British Journal of Psychiatry.

[66]  J. Teresi,et al.  Gender differences in cognition in schizophrenia , 1992, Schizophrenia Research.

[67]  G. Arbanas Diagnostic and Statistical Manual of Mental Disorders (DSM-5) , 2015 .

[68]  H. Elkis Treatment-resistant schizophrenia. , 2007, The Psychiatric clinics of North America.

[69]  E. Miller,et al.  An integrative theory of prefrontal cortex function. , 2001, Annual review of neuroscience.

[70]  R. C. Smith,et al.  Nonresponding schizophrenia: differentiation by neurological soft signs and neuropsychological tests. , 1999, Schizophrenia bulletin.

[71]  D. Velligan,et al.  Executive function in schizophrenia. , 1999, Seminars in clinical neuropsychiatry.

[72]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[73]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.